Orismilast, a Potent and Selective PDE4B /D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis
Experimental Dermatology · 2025
DOI: 10.1111/exd.70153 ↗At a glance
Klinische Studie (Phase II) in Experimental Dermatology, 2025. Written by Richard B Warren and 5 co-authors. Institution: Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK. Major MEDLINE topics: Cytokines, Phosphodiesterase 4 Inhibitors, Psoriasis, Skin. Cited 4 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: UNION therapeutics A/S.
Abstract (original language)
Minimally invasive sampling of the skin using tape strips for conducting biomarker research is a growing research area in medical dermatology. The goal of this study was to utilise tape strip sampling to investigate changes in protein skin levels of psoriasis patients after oral treatment with orismilast (a PDE4B/D inhibitor). The proteins were measured in extracts of tape‐strip samples taken from the skin of patients with moderate–severe psoriasis participating in a 16‐week Ph2b study (IASOS). The proteins were measured using the Olink technology or an ELISA assay. Our results show that protein levels of multiple proteins (32/71) were upregulated at baseline in the lesional skin compared to non‐lesional skin, including three key biomarkers of the psoriasis disease pathology (IL‐17A, CCL20 and TNFα). The protein levels of these three biomarkers were significantly reduced at Week 16, reaching a percent reduction of 52% and 51% for IL‐17A, 66% and 60% for TNFα, and 41% and 54% for CCL20 for the two doses analysed (20 and 30 mg bid, respectively). In addition, we observed that the clinical response of a 75% reduction in PASI (PASI75) was associated with a 98% reduction in IL‐17A protein levels in lesional skin, irrespective of the orismilast dose. In summary, a significant reduction of key proteins related to the T H 17 axis and T H 1 axis was observed in the skin of psoriasis patients after treatment with oral orismilast, supporting the observed clinical effect. Finally, this constitutes the first report where protein levels from the skin of psoriasis patients are quantified using tape strips as a minimally invasive skin sampling technology in combination with the Olink technology. Trial Registration: ClinicalTrials.gov identifier: NCT05190419
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.
- UNION Therapeutics A/S, Hellerup, Denmark.
- Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark (DTU), Lyngby, Denmark.
- Laboratory of Investigative Dermatology, The Rockefeller University, New York, New York, USA.
ORCID profiles: Anne Weiss, Morten O A Sommer, Sandra Garcet, James G Krueger
Funding
- UNION therapeutics A/S
Cite
APA
Warren, R. B., Weiss, A., Felding, J., Sommer, M. O. A., Garcet, S., & Krueger, J. G. (2025). Orismilast, a Potent and Selective PDE4B /D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis. Experimental Dermatology. https://doi.org/10.1111/exd.70153
Vancouver
Warren RB, Weiss A, Felding J, Sommer MOA, Garcet S, Krueger JG. Orismilast, a Potent and Selective PDE4B /D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis. Experimental Dermatology. 2025. doi:10.1111/exd.70153
BibTeX
@article{Warren2025,
author = {Warren, Richard B and Weiss, Anne and Felding, Jakob and Sommer, Morten O A and Garcet, Sandra and Krueger, James G},
title = {Orismilast, a Potent and Selective PDE4B /D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis},
journal = {Experimental Dermatology},
year = {2025},
doi = {10.1111/exd.70153}
}
EUVIMED